Working to detect cancer before tumors start.

Most people can survive cancer if it is caught early, so we have made that our goal.

Anpac Bio, founded in 2010, is drawing on diverse & extensive expertise. Since 2015 we have generated revenues providing cancer screening services in China with one of the largest global blood databases of over 140,000 samples.

A cross disciplinary team.

Cancer Research & Detection

Chemistry & Bio-chemistry

Nano-technology & Physics

Surface & Material Science

Engineering & Manufacturing

Our world class leaders started with the question, What if we could detect cancer before tumors start?

Co-Founders, Dr. Chris Yu and Dr. Herbert Yu have brought together a multi-national team of medical, biomedical and nanotechnology scientists, and engineering experts. Their cross-disciplinary approach combines numerous fields of science, medicine and engineering to achieve our innovative, patented early cancer screening and detection technology.

210 patent applications filed globally with 121 patent applications granted.*

Our patented Cancer Differentiation Analysis (CDA) technology requires only a standard blood sample from a tested individual to conduct an early cancer screening and detection test,  with no side effects in patients.

*As of September 30, 2019

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

©2019 Anpac Bio-Medical Science Co., Ltd.
;